Peptide PilotPeptide Pilot

mg ↔ units

Tirzepatide mg to units converter

Set your Tirzepatide vial concentration once, then flip in either direction between milligrams and U-100 syringe units.

Download Peptide PilotiPhone · Free to download

mg

2.500

units

50.0

mL

0.500

Concentration: 5.00 mg/mL (assumes a U-100 insulin syringe).

Tirzepatide is a once-a-week injection people use to lose weight and improve blood sugar control. It hits two gut-hormone receptors at once — GLP-1 and GIP — which is why it tends to drive larger appetite and weight changes than single-receptor drugs. In the SURMOUNT-1 trial, participants without diabetes lost roughly 20.9% of body weight over 72 weeks on the highest dose. This page covers reconstitution math and weekly dose logging.

How the Tirzepatide mg ↔ units converter works

This converter is a two-way bridge between dose mass (mg or mcg) and the unit count you actually draw on an insulin syringe. Once you set the Tirzepatide concentration of your current vial, you can type any mg value and read the units back, or type any unit count and read the mg back. It is the same math as the dose calculator, but bidirectional, which matters when you are checking a dose someone else recorded in units against a protocol written in mg.

The formula in both directions: mg = mL × concentration mg/mL, and units = mL × 100 on a U-100 syringe. With a 5 mg/mL Tirzepatide solution, 2.5 mg comes out to 50 units, and 50 units comes out to 2.5 mg. The converter handles the unit flip automatically so you never multiply or divide in your head while holding a syringe.

Concentration is the input that changes the answer most. A 10 mg vial diluted with 1 mL is twice as concentrated as the same vial diluted with 2 mL, which means the same dose draws half as many units. That is the single biggest source of converter confusion: a remembered unit count from an old vial does not transfer to a new vial reconstituted with different water volume.

Use the converter whenever a protocol or research note is written in one unit and your syringe is labeled in the other. It is also useful for sanity-checking that a planned titration step lands at a unit count you can read accurately on the syringe — under five units gets hard to read, over fifty starts crowding into the back third of a 1 mL syringe.

Why this matters for Tirzepatide

Tirzepatide is a synthetic peptide that activates two incretin receptors at once — GIP and GLP-1 — rather than only the GLP-1 receptor that semaglutide targets. That dual mechanism is what differentiates it from earlier GLP-1-only agonists. It is sold pharmaceutically under brand names including Mounjaro and Zepbound.

In a research and personal-logging context, tirzepatide is almost always supplied as a lyophilized powder in vials rated in milligrams of active peptide. Common vial sizes range from 5 mg up to 30 mg or larger, with 10 mg being one of the most frequently seen sizes in the research market.

Like semaglutide, tirzepatide has a long half-life — roughly five days — and is typically logged on a once-weekly cadence. That weekly rhythm shapes vial duration, refill planning, and how the dose escalation pattern is recorded over time.

Tirzepatide mechanism in plain English

Tirzepatide binds to both the GIP and GLP-1 receptors. Activating both at once influences insulin secretion in response to glucose and produces effects on appetite and gastric emptying. The dual-agonist design is what produces the differentiated weight and metabolic responses tirzepatide is associated with relative to single-receptor GLP-1 agonists.

Researchers and individuals tracking tirzepatide typically pair the weekly dose with weight, hunger ratings, and side-effect notes. The interesting trends only become visible across many weeks of consistent logging — single data points rarely tell the story.

At a molecular level, tirzepatide is a single, unimolecular peptide designed to function as an agonist for two distinct receptors: the GLP-1 receptor and the GIP receptor. While it shares GLP-1 receptor activity with other peptides in its category, its concurrent activation of the GIP receptor introduces a separate insulinotropic action. The primary structural feature that distinguishes tirzepatide from a single agonist like semaglutide is its specific, biased ratio of binding affinity for the GIP receptor relative to the GLP-1 receptor. This engineered affinity balance is a core element of its molecular architecture and documented function.

Tracking Tirzepatide unit counts

Tracking tirzepatide well means linking every dose log entry to the specific vial it came from, recording escalation dates explicitly, and pairing weekly metrics like weight and hunger ratings with the dose history. The escalation history in particular is hard to reconstruct from memory months later, which is why a structured log is more durable than scattered notes.

The escalating dose schedule directly impacts the process of tracking draw volumes, demanding meticulous record-keeping. Using a consistent vial concentration, such as the 5 mg/mL described previously, the logged volume changes with each titration step. A 2.5 mg dose is logged as 0.5 mL or 50 units, a 5 mg dose as 1.0 mL or 100 units, and a 7.5 mg dose as 1.5 mL, which corresponds to 150 units on a larger syringe. A digital tracking tool is critical to accurately convert each scheduled milligram dose to the correct unit measurement for the logbook, ensuring the documented data precisely reflects the protocol being observed without confusion between the different dose tiers.

Common Tirzepatide conversion mistakes

  • Reusing the unit count from a previous vial after switching to a new vial that was reconstituted with a different diluent volume.
  • Skipping the escalation date in the log, then being unable to answer when a dose change actually happened.
  • Mixing up tirzepatide milligrams with semaglutide milligrams — the doses are typically much larger for tirzepatide and the math is not interchangeable.
  • Underestimating doses-per-vial on a high-strength vial because the vial looks small even though it contains many weeks of supply.
  • Letting reconstituted tirzepatide sit at room temperature on travel days when a small cooler bag would have kept it refrigerated.
  • Failing to recalculate the correct unit volume for each new dose during a multi-step titration schedule.
  • Attempting to draw a volume greater than 1 mL, such as 1.5 mL or 3 mL, into a standard 1-mL insulin syringe.
  • Mistaking the GIP-to-GLP-1 binding affinity ratio, a fixed molecular property, for a variable that can be adjusted during reconstitution or administration.

Frequently asked questions about Tirzepatide mg ↔ units

How is tirzepatide reconstituted?
By drawing a measured volume of bacteriostatic water and injecting it slowly into the lyophilized vial through the rubber stopper, then swirling — not shaking — until the powder fully dissolves. Diluent volume choices typically range from 2 to 5 mL depending on vial strength and preferred per-dose unit count.
How many units of tirzepatide are in 2.5 mg?
It depends on the concentration. On a 10 mg vial reconstituted with 2 mL of bacteriostatic water (5 mg per mL), 2.5 mg is exactly 50 units on a U-100 syringe. With 4 mL of diluent (2.5 mg per mL), the same dose is 100 units.
Why is tirzepatide dosed weekly?
Because its half-life is roughly five days, which keeps plasma levels stable on a once-weekly schedule. That long half-life is also why a single missed dose has less effect than missing a dose of a daily peptide.
How long does a 10 mg tirzepatide vial last?
At a 2.5 mg weekly dose, a 10 mg vial supports 4 weeks of supply. The vial duration calculator runs the math for any combination of vial size, dose, and frequency.
Is tirzepatide stronger than semaglutide?
They activate different receptor combinations and are dosed at different milligram ranges, so direct milligram comparisons are misleading. The dual GIP/GLP-1 mechanism is the meaningful difference, not the raw milligram count.
Does tirzepatide need to be refrigerated?
Lyophilized powder is generally stored refrigerated, and the reconstituted vial is kept refrigerated and used within several weeks. A small insulated bag is the typical solution for keeping vials cold during travel.
Why does each new tirzepatide vial need its own log?
Because each vial may be reconstituted with a different diluent volume, producing a different concentration. Linking every dose entry to its specific vial keeps the unit count on the syringe accurate to that vial's real numbers.
How does the mechanism of tirzepatide differ from that of semaglutide?
The primary difference lies in their receptor targets. Semaglutide is a selective GLP-1 receptor agonist, meaning it is designed to activate only the GLP-1 receptor. Tirzepatide, in contrast, is a dual agonist, engineered as a single molecule that activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. Academic studies document that the addition of GIP receptor activity provides a secondary insulinotropic pathway, a feature not present in single-agonist GLP-1 peptides.
Why does the draw volume change so much when tracking a research protocol?
Protocols detailed in published studies often involve a dose titration, where the amount is systematically increased over time, for example from 2.5 mg up to 15 mg on a weekly cadence. If you reconstitute a vial to a fixed concentration, the volume needed to draw a specific dose will increase proportionally with the dose. This results in needing to calculate and draw a new, larger volume at each step of the titration schedule to obtain the correct milligram amount for that phase of the study.
What is the issue with drawing doses like 12.5 mg or 15 mg?
The challenge with higher doses is purely logistical and relates to administration volume. For a common concentration of 5 mg/mL, derived from a 10 mg vial reconstituted with 2 mL, a 12.5 mg dose requires a 2.5 mL draw, and a 15 mg dose requires a 3 mL draw. These volumes far exceed the capacity of common 1 mL insulin syringes. Therefore, researchers must plan ahead, either by using a larger syringe for administration or by reconstituting the peptide with more diluent to create a lower concentration per milliliter.

Related on Peptide Pilot

Save your Tirzepatide vial in the app

Download on the App Store
Get the App